nogalamycin and Liver-Diseases

nogalamycin has been researched along with Liver-Diseases* in 2 studies

Trials

1 trial(s) available for nogalamycin and Liver-Diseases

Article	Year
Tolerance of full dose menogaril (NSC 269148) in patients with abnormal hepatic and renal function. Investigational new drugs, 1990, Volume: 8, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drugs, Investigational; Female; Humans; Kidney Diseases; Liver Diseases; Male; Menogaril; Middle Aged; Nogalamycin; Prospective Studies	1990

Other Studies

1 other study(ies) available for nogalamycin and Liver-Diseases

Article	Year
[Pharmacokinetic studies of menogaril (TUT-7) with rats]. Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:11 Menogaril (TUT-7) is a novel antitumor antibiotic belonging to anthracyclines. The pharmacokinetic parameters derived from plasma concentration-time profiles after repeated (for 14 days) or single oral administration of TUT-7 to rats were found to be not significantly different by either administration schedule. The rats with artificial liver dysfunction were obtained by subcutaneous application of carbon tetrachloride (CCl4, 1 ml/kg) for 3 days. After oral administration of TUT-7 to the rats with CCl4-induced liver toxicity (3 daily administrations of 1mg/kg, S.C.), the maximum plasma concentrations (Cmax) and AUC of both the unchanged drug and its metabolite N-Demethyl menogaril, were increased. Also over all elimination was slower in animals with liver dysfunction. Topics: Administration, Oral; Animals; Antineoplastic Agents; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Liver Diseases; Male; Menogaril; Nogalamycin; Rats	1992

Article

Year

[Pharmacokinetic studies of menogaril (TUT-7) with rats].

Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:11

Menogaril (TUT-7) is a novel antitumor antibiotic belonging to anthracyclines. The pharmacokinetic parameters derived from plasma concentration-time profiles after repeated (for 14 days) or single oral administration of TUT-7 to rats were found to be not significantly different by either administration schedule. The rats with artificial liver dysfunction were obtained by subcutaneous application of carbon tetrachloride (CCl4, 1 ml/kg) for 3 days. After oral administration of TUT-7 to the rats with CCl4-induced liver toxicity (3 daily administrations of 1mg/kg, S.C.), the maximum plasma concentrations (Cmax) and AUC of both the unchanged drug and its metabolite N-Demethyl menogaril, were increased. Also over all elimination was slower in animals with liver dysfunction.

Topics: Administration, Oral; Animals; Antineoplastic Agents; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Liver Diseases; Male; Menogaril; Nogalamycin; Rats

1992